lianhua qingwen contraindication

6 (01), 6364. The Cochrane Collaboration risk of bias tool comprising seven items was applied to assess the risk of bias of each eligible study (Higgins et al., 2011). The novel coronavirus disease 2019 (COVID-19) has become a matter of international concern as the disease is spreading exponentially. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. [Fabaceae; Glycyrrhizae Radix et Rhizoma] (85g) (Rivera et al., 2014; Royal Botanic Gardens, Kew, 2021; Royal Botanic Gardens, Kew science, 2021; The Plant List, 2021; Yiling Pharmaceutical, 2021). (2015). Li Q., Yin J., Ran Q.S., Yang Q., Liu L., Zhao Z., Li Y.J., Chen Y., Sun L.D., Wang Y.J., Weng X.G., Cai W.Y., Zhu X.X. For hand-foot-mouth disease, sample size (p = 0.082), year of publication (p = 0.795), and treatment of the control group (p = 0.701) did not explain the issue of heterogeneity. Pulmonary Rale.Eighteen studies reported an effect on the duration of pulmonary rale. As the Financial Times report showed, these appeared to be serious conflicts of interest as the investments benefited from the PRC and HK governments' rapid approval and then widespread national & international promotion of Lianhua Qingwen and other suspect treatments for purportedly helping COVID-19 sufferers. These in vitro studies indicate that LHQW shows a wide range of antiviral activities including its anti-SARS-CoV-2 role. Res. Jia W., Wang C., Wang Y., Pan G., Jiang M., Li Z., Zhu Y. Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS. Wang C.H., Zhong Y., Zhang Y., Liu J.P., Wang Y.F., Jia W.N., Wang G.C., Li Z., Zhu Y., Gao X.M. Chinese Herbal Medicine ("3 Medicines and 3 Formulations") for COVID 19: Rapid Systematic Review and MetaanalysisChinese Herbal Medicine ("3 Medicines and 3 Formulations") for COVID-19: Rapid Systematic Review and Meta-Analysis. The group reported significantly lower incidence of adverse reactions (RR = 0.62, 95% CI = 0.460.82) and lower incidence of gastrointestinal system damage in the LHQW group (RR = 0.65, 95% CI = 0.460.92) relative to the control group. There was no statistically significant difference in the incidence of adverse reactions during treatment of herpes zoster between the LHQW group and the conventional drug group (RR = 0.80, 95% CI = 0.521.23, p = 0.302). Besides, in view of the definite effects of LHQW in preventing severe viral infections such as SARS and COVID-19 [17,44,45,49,52,53], LHQW may represent a considerable and effective strategy against unknown viral epidemics. Here, we performed a meta-analysis of 217 Chinese experimental studies to evaluate the safety of LHQW. Lianhua Qingwen can be a complementary strategy for treating COVID-19. government site. [14] Retraction Watch also notes that author Jia Zheng-hua is the son-in-law of Wu Yi-ling, the founder of the company in question. Z., Wang, H. T., Han, X., Liu, C., Sun, Y. N., Liu, B., et al. Clinical Drug Safety of Lianhuaqingwen Preparation: a Systematic Evaluation. FOIA 38 studies reported dispose or outcomes of adverse reactions. Li L.C., Kan L.D. Traditional Med. Trim and Fill: a Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis. Now, there are no study results posted on ClinicalTrials.gov for this study yet. CFDA has recently approved adding a new indication for LHQW in mild and common COVID-19 patients, but whether it would bring benefits for the severe cases is unclear. Reports emerged indicating that this process consumed significant logistical capacity, drawing criticism about misuse of resources at a time when people were struggling with shortages of basic needs such as food and medication. 339 (7), b2535. However, no consensus has been reached on the security of LHQW to date. After 7 days of treatment, the main TCM syndrome scores (fever, fatigue, cough, dry throat, chest tightness), C-reactive protein and procalcitonin levels in the LHQW group were significantly lower, and the white blood cell and lymphocyte counts were obviously higher than those in abidor group [44]. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Available at: http://www.yiling.cn/contents/75/132.html (Accessed September 14, 2021). Assoc. (2015). Contraindications . Overall, 61 chemical compounds of LHQW (including iridoids, flavonoids, anthraquinones, phenylpropanoids, triterpenoids, and other types) have been unambiguously or tentatively identified via rapid ultra-performance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry (Jia et al., 2015). Introduction As the global epidemic continues to spread, countries have tapped effective drugs to treat new coronavirus pneumonia. As adverse reactions in COVID-19 pneumonia and chronic obstructive pulmonary disease treatment were only reported for a limited number of studies, no sensitivity analysis for these diseases was conducted. LHQW is one of the TCM formulations that have been officially approved to treat COVID-19 patients, which may be due to its antiviral, lung protection, and regulation of inflammation response as well as immune regulation actions (Fig. Subgroup analysis showed a lower level of nausea or vomiting in LHQW group (RR = 0.60, 95% CI = 0.480.74, p < 0.001), no statistical difference was detected for other symptoms of gastrointestinal system damage. Wu, L., Chen, Y., Ma, Y., Yang, Z., Yang, N., Deng, W., et al. [Cruciferae; Isatudus Radix], Dryopteris crassirhizoma Nakai [Polypodiaceae; Dryopteris Crassirhizomatis Rhizoma], Houttuynia cordata Thunb. Combined with western medicine conventional therapy in the treatment of 63 suspected cases of Coronavirus Disease 2019. Lianhua Qingwen (simplified Chinese: ; traditional Chinese: ; lit. Though the quality of the included literature was mixed, the lung protection effects of LHQW was demonstrated. National Administration of Traditional Chinese Medicine: Traditional Chinese Medicine Is Involved in a Wide Range of Treatment and Early Intervention Has Good Effects. A total of 2,511 citations were identified, among which 1,796 irrelevant, animal studies or duplicate studies were excluded, for screen of titles and abstracts. Results were reported as risk ratio (RR) with 95% confidence interval (CI). Based Complement. doi:10.5582/ddt.2020.03008, PubMed Abstract | CrossRef Full Text | Google Scholar, Cao, B., Zhang, D., and Wang, C. (2020). Six studies were included on treatment of herpes zoster and reported the adverse reactions. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Clin. Clin. Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. Figure 1 provides a detailed flowchart of the screening process. No proven effective antiviral treatments for COVID-19 pneumonia are available at present (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). Yang C.X., Qu J., Liu Y.T., Meng S.W., Wang B.L., Feng M.Q., Sun Y. Clin. Several limitations of our meta-analysis should be taken into consideration. Some composition of LHQW can cause damage to the stomach and intestines, supporting the possibility of injurious effects on the gastrointestinal system: for thia suspensa (Thunb.) Lianhua Qingwen Prescription is approved for the treatment of fever, cough, and fatigue caused by light and common type of COVID-19 . The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. It cannot be taken as prophylaxis or as a health supplement. Declaration of competing interest. Chen J., Wang Y.K., Gao Y., Hu L.S., Yang J.W., Wang J.R., Sun W.J., Liang Z.Q., Cao Y.M., Cao Y.B. Otherwise, the fixed-effects model was used (DerSimonian and Laird, 1986; Higgins et al., 2003). These above ingredients are decocted, distilled, filtered, refrigerated, mixed well with powdered sugar, dextrin or starch, dried and finally made into LHQW (Chinese Pharmacopoeia, 2020). 6 (26), 8485. No statistical difference was detected for sleepy. ChemRxiv. Effects of Four Types of Integrated Chinese and Western Medicines for the Treatment of Covid-19 in china: a Network Meta-Analysis. Available at: http://www.plantsoftheworldonline.org (Accessed December 18, 2021). Pregnancy & lactation. Eval. [7] In the United States, the FDA is advising consumers not to purchase or use Lianhua Qingwen, stating that it has not been approved or authorized by FDA and is being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Significant heterogeneity was detected for COVID-19 pneumonia (I2 = 76.0), hand-foot-mouth disease (I2 = 62.1), rheum (I2 = 88.2), and drowsiness of nervous system damage (I2 = 91.8). Warning 1. doi:10.11816/cn.ni.2015-134443. Traditional Chinese medicine treatment maintains homeostasis through interactions between the body and pathogens or establishing a balance between stimulating antiviral responses and suppressing overactive immune responses that leads to tissue damage (Shi et al., 2021). Fujian J. Clinical Practice Guideline on Treating Influenza in Adult Patients with Chinese Patent Medicines. Recent clinical evidence also showed that LHQW in combination with western medicines, such as the other antiviral drugs, is better than that not using LHQW during COVID-19 treatment, suggesting it would be beneficial as a supplementary strategy for treating COVID-19 [41,[44], [45], [46]]. Lianhua Qingwen Capsules has a better therapeutic effect on viral influenza, but the incidence of adverse reactions is high, and its safety must be taken seriously. Meta-Analysis of Efficacy of Oseltamivir and Substitution Therapy for Anti- H1n1 Infection. LHQW also decreased the influenza viral titers in the lungs of mice, with decreased inflammatory cytokine levels in the early stages of infection [24]. The different incidence of these adverse reactions may be related to the metabolic level, which varies greatly among the different age groups. For thousands of years, traditional Chinese medicine (TCM) plays an important role in treating human diseases [[9], [10], [11], [12], [13], [14]]. Meta-analysis in Clinical Trials. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Hence, the researches on specific active components of LHQW are still important and the reduction of irrelevant ingredients may be related to less adverse reactions. Lian Hua Qing Wen capsules (LHQW) is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China. (2020). For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). 25 (4), 727790728729. Seven studies reporting treatment of chronic obstructive pulmonary disease were included, among which two described adverse reactions. Finally, 217 experimental studies on the Chinese population were included for study featuring 1759 cases of adverse reactions following clinical treatment (publication years ranging from 2005 to 2021). 367 (6485), 14121413. TABLE 2. In conclusion, this review has summarized the benefits of LHQW for treating virus infection, especially its anti-SARS-CoV-2 role as an alternative candidate and complementary strategy. 12 (08), 140141. Efficacy of Huoxiang Zhengqi Dropping Pills and Lianhua Qingwen Granules in Treatment of Covid-19: a Randomized Controlled Trial. The post-marketing monitoring data incorporated information on the following gastrointestinal adverse reactions: nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth; as well as skin rash, itching, dizziness (Yiling Pharmaceutical, 2021). Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. Lianhua-qingwen Displays Antiviral and Anti-inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. Six studies reported the adverse reactions of abnormal white blood cells and reticuloendothelial system. The recent meta analysis reported 22 studies with a total of 2,007 patients, showing that the adjuvant therapy of LHQW with western medicine could improve the clinical efficiency and C-reactive protein index, shorten the time of antifebrile, cough time, rhondros duration and imaging time, as well as speed up the recovery of pneumonia patients [39]. Pharmacol. Second, the herbs in LHQW are mostly grown in specific areas, the varied origin of herbs are usually together with different content of bioactive ingredients, thus the quality standard control of the included crude drugs should be encouraged [12]. The term adverse reaction represents any undesired and unintended response that occurs with normal drug use (Gallelli et al., 2002). There was no statistically significant difference in the incidence of abnormal white blood cells and reticuloendothelial system between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.382.62, p = 1.000). COPD is characterized by a chronic inflammatory response and can be worsened by acute exacerbations. Skin rashes, allergic dermatitis and other skin allergic reactions are also reported to be associated with LHQW treatment, and may be related to Houttuynia cordata Thunb. Res. 37 (6), 25752579. 160, 105101. doi:10.1016/j.phrs.2020.105101, Xiao, M., Tian, J., Zhou, Y., Xu, X., Min, X., Lv, Y., et al. Med. 3.2.2. In recent years, LHQW has been registered to obtain marketing authorization in Canada, Brazil, Singapore, Thailand, the Philippines, Kuwait and other countries under the designation Chinese patent medicine, medicine, physical natural health products, food supplement, modern botanical medicine or natural medicine (Yiling Pharmaceutical, 2020). Beijing: China Medical Science Press. We aim to assess the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection. There was a reduced risk of skin and its appendage damage in the LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.440.92, p = 0.015). Upon full text filtering of the remaining 715 citations, 498 were excluded due to a number of reasons (shown in Figure 1). doi:10.1007/s12325-020-01351-9, Kupferschmidt, K., and Cohen, J. (Nat. The following information was collected from each qualifying study: first authors name, year, treating disease, sample size, number of male and female, age, adverse reactions, dispose or outcome of adverse reactions. Research progress in use of traditional Chinese medicine for treatment of spinal cord injury. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. Kong Q., Wu Y., Gu Y., Lv Q., Qi F., Gong S., Chen X. Ding Y., Zeng L., Li R., Chen Q., Zhou B., Chen Q., Cheng P.L., Yutao W., Zheng J., Yang Z., Zhang F. The Chinese prescription Lianhua Qingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function.

Estranged Parents Support Group Near Me, Articles L